Teleflex (TFX) delivered earnings and revenue surprises of +37.50% and +1.89%, respectively, for the quarter ended June 2026.

Medical technology company Teleflex (NYSE:TFX) reported Q2 CY2026 results , with sales up 28.9% year on year to $570.3 ...

Military trauma experts say a newly approved plasma product could help expand lifesaving care far from hospitals.

The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of $1.28 per share. The medical ...

Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing ...

Explore Teleflex FDA-approved plasma platform, healthcare operations, trauma care technologies, product developments, and S&P ...

Medical technology company Teleflex (NYSE:TFX) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with ...

Teleflex Incorporated has announced a contract with Vizient, Inc. for the supply of its Central Venous Access Catheters and Arterial Catheters, effective January 1, 2025. Vizient, the largest provider ...

Teleflex reported Q1 2026 continuing operations revenue of $548.3 million, up 32.3% year over year on a GAAP basis, reflecting the impact of acquisitions. On a pro forma adjusted constant currency ...

Teleflex may be enjoying improved profits and sales. But it will still lay off workers and close plants as it restructures in the face of what top executive Benson F. Smith describes as "continuing ...

Ratings for Teleflex (NYSE:TFX) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...